newsfilter
← Latest News
Business Wire·

MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab

- Total proceeds expected to be approximately $230 million, combining funds held in Helix Acquisition Corp's trust account and a private investment in public entity (PIPE) financing - Leading institutional investors commit $115 million through a PI